Eye News and Research

Latest Eye News and Research

Stiff skin syndrome cause found

By studying the genetics of a rare inherited disorder called stiff skin syndrome, researchers at the Johns Hopkins University School of Medicine have learned more about scleroderma, a condition affecting about one in 5,000 people that leads to hardening of the skin as well as other debilitating and often life-threatening problems. The findings, which appear this week in Science Translational Medicine, open doors to testing new treatments.

18 Mar 2010

ISCO commences second phase of testing RPE derived from parthenogenetic stem cells

International Stem Cell Corporation, announced today that ISCO's Research and Therapeutic Development Group, together with a group of scientists from the University of California, Irvine (UCI), is starting a second phase of essential pre-clinical experiments to test retinal pigment epithelium derived from parthenogenetic stem cells. Follow on pre-clinical experiments will be conducted to rescue vision in disease models.

18 Mar 2010

Manitoba government: AMD drug Lucentis will be funded through centralized vision program

Manitobans with wet age-related macular degeneration (AMD) received a dose of good news. The Manitoba government announced that Lucentis (ranibizumab injection) will soon be funded through a centralized vision program, effective June 1, 2010.

18 Mar 2010

Academic Inventors’ Bill of Rights unveiled in poster presentation at AUTM Annual Meeting

As technology transfer managers from around the country prepare today to debate the role of academic researchers in commercializing their own inventions, two experts – one from each side of the aisle – have come together to propose an Academic Inventors’ Bill of Rights.

18 Mar 2010

Scientific revelations discovered during Retina Implant’s first human clinical trial

Retina Implant, AG, a leading developer of subretinal implants for the visually impaired, today announced scientific revelations discovered during the company’s first human clinical trial. The results achieved in the 11 patients that were involved in the trial exceeded the company’s expectations for their first trial.

18 Mar 2010

House Democratic leader twisting arms of the rank-and-file; Tracking health reform vote tally

Democrats are pressuring fellow members to accept the health care reform legislation and are playing hardball to secure votes for the health reform package.

18 Mar 2010

Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced that they have received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACU-4429, an investigational oral treatment for dry age-related macular degeneration (dry AMD).

17 Mar 2010

First Edition: March 17, 2010

Today's news continues to focus on Democratic leaders' efforts to finalize their health reform package and gather the votes necessary to gain House passage.

17 Mar 2010

Researchers develop new analytical method to process large amounts of information faster

Researchers at North Carolina State University have developed a new analytical method that opens the door to faster processing of large amounts of information, with applications in fields as diverse as the military, medical diagnostics and homeland security.

17 Mar 2010

OVD issue highlights prevalence of eye problems in general population

In the latest issue of Optometry & Vision Development (OVD), Dr. Dominick Maino, editor of OVD, notes that: "In 2010 there are 9 million people with lazy eye and 18 million individuals with eye-turns

17 Mar 2010

Promedior raises $12M in Series C financing

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.

16 Mar 2010

Perrigo introduces generic Zaditor

Perrigo Company today announced that it has begun shipping Ketotifen Fumarate ophthalmic solution, 0.025%, a generic version of Zaditor™.

15 Mar 2010

Inspire Pharmaceuticals reports results of two AZASITE Phase 2 clinical trials for blepharitis

Inspire Pharmaceuticals, Inc. announced today the results from two Phase 2 clinical trials with AZASITE (azithromycin ophthalmic solution) 1% for the treatment of blepharitis. Inspire will conduct additional clinical work to continue pursuing a potential indication for treatment of anterior and posterior forms of blepharitis.

15 Mar 2010

OXiGENE signs definitive agreement to sell Common Stock

OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has entered into a definitive agreement with certain institutional investors to sell 6,578,945 shares of its Common Stock and separate series of warrants to purchase Common Stock in a private placement.

12 Mar 2010

Study explores incidence of eating disorders among type 1 diabetic patients

Diabetics, under the gun to better manage their disease by controlling their food intake and weight, may find themselves in the sticky wicket of needing treatment that makes them hungry, researchers said.

12 Mar 2010

Age-related macular degeneration affects central vision in older Americans

Indianapolis resident Harry Traugott was an active retiree, participating in community events, driving and even teaching English as a second language at two community centers. He’d been diagnosed with age-related macular degeneration (AMD), but the disease had not caused significant vision loss. It wasn’t until he had trouble seeing while driving, watching television

11 Mar 2010

StemCells reports net loss of $5.23M for fourth-quarter fiscal 2009

StemCells, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. The Company's results include the operations of Stem Cell Sciences Plc (SCS) since April 1, 2009.

11 Mar 2010

Auditory cortex development becomes vulnerable if it does not receive appropriate stimulation at right time

Hearing scientist Daniel Polley, Ph.D., an investigator at Massachusetts Eye and Ear Infirmary's Eaton-Peabody Laboratories of Auditory Physiology, has gained new insight into why a relatively short-term hearing deprivation during childhood may lead to persistent hearing deficits, long after hearing is restored to normal.

11 Mar 2010

Bioness announces two agreements to distribute new devices for patients with neurological impairment

Bioness Inc., a leading neuromodulation company, announced today two agreements to distribute new devices for patients experiencing neurological impairment. Through the agreements with Performance Enterprises and Aretech™, LLC, Bioness is now distributing the Dynavision D2™ Visuomotor Training System and the ZeroG™ Overground Gait and Balance Training System to rehabilitation centers and hospitals.

11 Mar 2010

$TLCVision to incorporate TearLab Osmolarity System to study DED in refractive surgery centers$

TLCVision to incorporate TearLab Osmolarity System to study DED in refractive surgery centers

OccuLogix, Inc., dba TearLab Corporation, announced today that TLCVision Corporation, North America's premier eye care services company, will be incorporating the TearLab™ Osmolarity System in eight of its U.S. refractive surgery centers to study Dry Eye Disease symptoms as they relate to LASIK surgery.

11 Mar 2010

Eye News and Research

Latest Eye News and Research

Stiff skin syndrome cause found

ISCO commences second phase of testing RPE derived from parthenogenetic stem cells

Manitoba government: AMD drug Lucentis will be funded through centralized vision program

Academic Inventors’ Bill of Rights unveiled in poster presentation at AUTM Annual Meeting

Scientific revelations discovered during Retina Implant’s first human clinical trial

House Democratic leader twisting arms of the rank-and-file; Tracking health reform vote tally

Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD

First Edition: March 17, 2010

Researchers develop new analytical method to process large amounts of information faster

OVD issue highlights prevalence of eye problems in general population

Promedior raises $12M in Series C financing

Perrigo introduces generic Zaditor

Inspire Pharmaceuticals reports results of two AZASITE Phase 2 clinical trials for blepharitis

OXiGENE signs definitive agreement to sell Common Stock

Study explores incidence of eating disorders among type 1 diabetic patients

Age-related macular degeneration affects central vision in older Americans

StemCells reports net loss of $5.23M for fourth-quarter fiscal 2009

Auditory cortex development becomes vulnerable if it does not receive appropriate stimulation at right time

Bioness announces two agreements to distribute new devices for patients with neurological impairment

TLCVision to incorporate TearLab Osmolarity System to study DED in refractive surgery centers

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Eye News and Research

Latest Eye News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in